載入中
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
前收盤價
US$2.02
−US$0.12 · -5.61%
盤後
US$2.13
+US$0.11 · +5.45%
10月12日 下午7:32 ET
盤中時間採用ET。市場資料可能有所延遲。
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
日內區間
目前US$2.02
52週區間
目前US$2.02
盤中時間採用ET。市場資料可能有所延遲。
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
日內區間
目前US$2.02
52週區間
目前US$2.02
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | — | — | 1230.5萬 USD |
| 毛利 | — | — | — | — | −1230.5萬 USD |
| 研究與開發 | 1.05億 USD | 9379.8萬 USD | 4231.8萬 USD | 3236.1萬 USD | 1230.5萬 USD |
| 銷售、一般及管理費用 | 1894.7萬 USD | 2021.9萬 USD | 1882萬 USD | 1287.6萬 USD | 727.9萬 USD |
| 營業費用 | 1.24億 USD | 1.14億 USD | 6113.8萬 USD | 4523.7萬 USD | 727.9萬 USD |
| 利息收入 | 744.7萬 USD | 1431.7萬 USD | 1079.1萬 USD | 239.2萬 USD | 8.4萬 USD |
| 利息支出 | 422.4萬 USD | 406.8萬 USD | 58.1萬 USD | — | — |
| 折舊和攤銷 | 18.4萬 USD | 17.8萬 USD | 18.4萬 USD | 16.9萬 USD | 4000 USD |
| 營業利益 | −1.24億 USD | −1.14億 USD | −6113.8萬 USD | −4523.7萬 USD | −1958.4萬 USD |
| 淨利 | −1.21億 USD | −1.02億 USD | −5237.1萬 USD | −4285.6萬 USD | −1.01億 USD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
